Destined for the president’s signature are two bipartisan bills that aim to boost generic and biosimilar competition by restricting eligibility for drug exclusivity and by increasing confidence in biosimilars.
NON-SUBSCRIBER OPTIONS
FREE TRIAL | NEWSSTAND
Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.
Log in to access this content.
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.
© 2002-2021. Inside Washington Publishers | Contact Us